Disclaimer
Het alfapump®-systeem is momenteel niet goedgekeurd in de Verenigde Staten of Canada. In de Verenigde Staten en Canada wordt het alfapump®-systeem momenteel klinisch onderzocht (POSEIDON-studie) en wordt het bestudeerd bij volwassen patiënten met refractaire of terugkerende ascites als gevolg van levercirrose. DSR®-therapie is nog in ontwikkeling en er dient te worden opgemerkt dat eventuele verklaringen met betrekking tot veiligheid en efficiëntie voortkomen uit lopende preklinische en klinische onderzoeken die nog moeten worden afgerond. Er is geen verband tussen de DSR®-therapie en de lopende onderzoeken met het alfapump®-systeem in Europa, de Verenigde Staten of Canada.
We are a pioneer in treating drug-resistant fluid overload, a serious and frequent clinical complication in patients with liver disease, heart failure and cancer. alfapump® and DSR® are Sequana Medical’s proprietary approaches that work with the body to remove this excess fluid, delivering major clinical and quality of life benefits for patients and reducing costs for healthcare systems. We are listed on Euronext Brussels, headquartered in Ghent, Belgium and also have offices in Zurich, Switzerland.
We embrace diversity and inclusion. You will have the opportunity to work with outstanding business teams and contribute to the success of the company. We strive to provide all our employees with the means to develop their skills and experiences, at every level.
The HR Generalist reports to the HR Manager and will act as an expert for HR operations, payroll & benefits queries, and processes for internal and external partners in Belgium.
The HR Generalist acts as a point of contact for employees with the aim of providing optimal support in the development and execution of the HR policies and processes. Furthermore, the HR Generalist brings organizational and administrative support within one or more HR Domains.
Administrative & Payroll:
Compliance:
Projects:
We offer a full time (100%) contract in a very dynamic and international environment with an attractive salary package at our Ghent office.
If you are interested, please send your resume and motivation to careers@sequanamedical.com
The IT System Administrator needs to ensure the proper functioning of existing IT infrastructures, to maintain them and to make them evolve according to the needs and new technical solutions.
We offer a full time (100%) contract in a very dynamic and international environment with an attractive salary package at our Zürich office.
If you are interested, please send your resume and motivation to careers@sequanamedical.com
The employee is responsible for supporting the execution of Sequana Medical’s clinical studies and programs in line with the company’s clinical development programs, under supervision of the Global Director Clinical Operations.
We offer a part time / full time (80%-100%) contract in a very dynamic and international environment with an attractive salary package at our Ghent office.
If you are interested, please send your resume and motivation to careers@sequanamedical.com
De alfapump® is nog steeds in klinisch onderzoek in de VS en Canada en daarom zijn alle uitspraken met betrekking tot veiligheid en werkzaamheid niet van toepassing in deze gebieden.
De DSR-therapie is nog in ontwikkeling en het moet worden opgemerkt dat alle uitspraken met betrekking tot veiligheid en werkzaamheid voortkomen uit lopend preklinisch en klinisch onderzoek dat nog moet worden voltooid.
Er is geen verband tussen de DSR-therapie en lopende onderzoeken met het alfapump® systeem in Europa, de VS en Canada.
U.S. Centers for Disease Control and Prevention, Health, United States 2016, Chartbook on Long-term trends in Health, Table 20 (website)
GlobalData NASH Epidemiology Forecast to 2026
Runyon et al. (2009)
Europese Vereniging voor Leveronderzoek EASL richtlijnen klinische praktijk voor het beheer van ascites, spontane bacteriële buikvliesontsteking en hepatorenaal syndroom bij cirrose. Journel of Hepatology. 2010 vol. 53. 397-417. p. 402.
Wereldgezondheidsorganisatie Internationaal Agentschap voor Kankeronderzoek 2018 (http://gco.iarc.fr/today/home) (geschat aantal nieuwe borst- en eierstokkankers in 2018 (bruto cijfer))
Ayantunde et al. (2006)
Benjamin et al. (2013)
Costanzo et al. (2007)
Kilgore et al. (2017)
Kilgore et al. (2017); Ambrosy et al. (2014)
Testani JM, Hanberg JS, Cheng S, et al. Rapid and Highly Accurate Prediction of Poor Loop Diuretic Natriuretic Response in Patients With Heart Failure. Circulation Heart failure. 2016;9(1):e002370. doi:10.1161/CIRCHEARTFAILURE.115.002370.
Ginès et al. (2004) (verklarende dat refractaire ascites zich voordoet bij 5 tot 10 procent van de patiënten met ascites)
Estes et al. (2018)